WO2024030474A1

WO2024030474A1 - Light-modulating cosmetic compositions and uses thereof

Info

Publication number: WO2024030474A1
Application number: PCT/US2023/029282
Authority: WO
Inventors: Audrey MANIERE; Julie LEIGNADIER; Joan ATTIA
Original assignee: Lucas Meyer Cosmetics Sas
Priority date: 2022-08-03
Filing date: 2023-08-02
Publication date: 2024-02-08

Abstract

Provided herein are cosmetic compositions capable of modulating light emitted from non-uniform light-emitting sources to balance the light received, e.g., irradiance, on a target tissue, and consumer products containing light-modulating cosmetic compositions. Also provided are methods of making and using light-modulating cosmetic compositions and consumer products.

Description

LIGHT-MODULATING COSMETIC COMPOSITIONS AND USES THEREOF

CROSS-REFERENCE TO RELATED APPLICATION

[001] This application claims priority from U.S. provisional application No. 63/394,751, filed August 3, 2022, the contents of which are hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

[002] Provided herein are cosmetic compositions capable of modulating light emitted from non- uniform light-emitting sources to balance the light received, e.g., irradiance, on a target tissue, and consumer products containing light-modulating cosmetic compositions. Also provided are methods of making and using light-modulating cosmetic compositions and consumer products.

BACKGROUND

[003] Unlike the sun, which emits a balanced visible light spectrum called white light, digital screens from computers and smartphones and other artificial light sources (e.g., fluorescent lights, LEDs) emit unbalanced (non-uniform) light with an intense peak in the blue light range. While white light has beneficial effects on the skin and subject’s well-being, artificial light is associated with, among other things, biological skin perturbations. In spite of this, adults spend substantial periods of time in front of non-uniform light-emitting sources (e.g., computer screens) which can negatively impact skin health and overall well-being.

[004] Typical strategies for protecting against the negative effects of non-uniform light-emitting sources attenuate the emitted blue light. However, these strategies do not modulate the light emitted from non-uniform light-emitting source to generate a balanced irradiance profile capable of producing a beneficial result. There is thus a need for new strategies to convert potentially harmful light emitted from non-uniform light sources to more balanced light, e.g., white light, capable of delivering beneficial effects. Provided herein are compositions and methods that address these and other needs in the art.

SUMMARY OF THE INVENTION

[005] In an aspect is provided a light-modulating cosmetic composition including one or more photoluminescent compounds, wherein the composition modulates an irradiance of a non-uniform light-emitting source on a target tissue. [006] Tn an aspect is provided a consumer product including a light-modulating cosmetic composition described herein. In some embodiments, the consumer product is a cream, a lotion, a gel, a foam, a paste, a salve, a balm, a varnish, or an ointment.

[007] In an aspect is provided a method of modulating an irradiance from a non-uniform lightemitting source on a target tissue, including topically applying a light-modulating cosmetic composition or a consumer product described herein to a target tissue.

[008] In an aspect is provided a method of reducing or preventing photodamage to a target tissue from a light emitted from a non-uniform light-emitting source, including topically applying a lightmodulating cosmetic composition or a consumer product described herein to a target tissue.

[009] In an aspect is provided a method of reducing or preventing aging of a target tissue from a light emitted from a non-uniform light-emitting source, including topically applying a lightmodulating cosmetic composition or a consumer product described herein to a target tissue.

[0010] In an aspect is provided a method of reducing or preventing oxidative stress of a target tissue from a light emitted from a non-uniform light-emitting source, including topically applying a light-modulating cosmetic composition or a consumer product described herein to a target tissue.

[0011] In an aspect is provided a method of modulating photoactivation of a chromophore in a target tissue by a light emitted from a non-uniform light-emitting source, including topically applying a light-modulating cosmetic composition or a consumer product described herein to a target tissue.

[0012] In an aspect is provided a method of improving an appearance of a target tissue exposed to a light emitted from a non-uniform light-emitting source, including topically applying a lightmodulating cosmetic composition or a consumer product described herein to a target tissue.

[0013] In an aspect is provided a method of improving a well-being of a subject exposed to a light emitted from a non-uniform light-emitting source, including topically applying a light-modulating cosmetic composition or a consumer product described herein to a target tissue.

[0014] In an aspect is provided a method of making a consumer product, including: (a) adding to a cosmetic base a light-modulating cosmetic composition described herein to form a mixture; and (b) stirring the mixture to achieve homogeneity. In some embodiments, the method includes emulsifying the mixture. Tn some embodiments, the method includes cooling the mixture. Tn some embodiments, the method includes adjusting the pH of the mixture.

[0015] In an aspect is provided a kit comprising a light-modulating cosmetic composition as described herein and instructions for use.

[0016] Each of the aspects and embodiments described herein are capable of being used together, unless excluded either explicitly or clearly from the context of the embodiment or aspect.

BRIEF DESCRIPTION OF THE DRAWINGS

[0017] FIG. 1 shows the coupled absorption and emission spectra of an exemplary Test Mix (see, Section V, Table El). The emission spectrum was obtained by illuminating the exemplary Test Mix with a monochromatic light at 455 nm.

[0018] FIG. 2 shows the experimental design for assessing the light transforming effect of the exemplary Test Mix (see, Section V, Table El) when illuminated by a digital screen.

[0019] FIG. 3 shows an exemplary computer screen emission spectrum (30 cm).

[0020] FIGS. 4A-4B show the visible light modulation, determined by measuring irradiance, of an exemplary Test Mix (see, Section V, Table El) when illuminated by an exemplary computer screen (FIG. 4A) or an exemplary smartphone screen (FIG. 4B) at a distance of 30 cm under three environmental conditions: in darkness (Dark), under natural light (in the vicinity of a window; Natural Light), and in the presence of LED panels (Artificial Light). FIGS. 4C-4E show hourly measured irradiance over 8 hours of the exemplary Test Mix and Placebo at 450 nm (FIG. 4C), 540 nm (FIG. 4D), and 600nm (FIG. 4E), when illuminated with an exemplary computer screen (30 cm) in a dark environment (no natural or artificial light).

[0021] FIG. 5 shows the average percentage ± standard deviation of positive surface for 8-OHdG staining in skin explants that were untreated and not exposed to blue light, untreated and exposed condition to blue light, treated with Placebo and exposed to blue light, and treated with an exemplary Test Mix and exposed to blue light (see, Section V, Table El). The results were normalized to the untreated, unexposed reference condition. Statistical significance was assessed using the Mann-Whitney test (****p<0.0001).

[0022] FIG. 6 shows the average percentage ± standard deviation of Cytochrome c oxidase (CCO) activity in skin explants that were untreated and not exposed to blue light, untreated and exposed to blue light, treated with Placebo and exposed to blue light, and treated with an exemplary Test Mix and exposed to blue light (see, Section V, Table El). The results were normalized to the untreated, unexposed reference condition. Statistical significance was assessed using the Unpaired T test (***p<0.0001, **p<0.001, #p<0.1).

[0023] FIG. 7A shows opsin 1SW expression, using immunostaining, in heathy human explants treated with an exemplary Text Mix (see, Section V, Table El), Placebo, or untreated, after 8 days of daily exposure to blue light. FIG. 7B shows opsin 2 expression, using immunostaining, in heathy human explants treated with the exemplary Text Mix, Placebo, or untreated, after 8 days of daily exposure to blue light. FIG. 7C shows the average percent ± standard deviation of surface stained for opsin 1 SW and opsin 2 across treatment conditions. The values are normalized to 100% of the untreated, unexposed condition. Significance levels are set to *p< 0.05, **p<0.01, ***p<0.001 using the Mann-Whitney test.

[0024] FIG. 8A shows emission at 512 nm of an exemplary photoluminescent mixture (see, Example 1) in electromagnetized and non-electro magnetized water immediately following blue light exposure (482 nm). FIGS. 8B-8C show a drop containing 0.00015% of the photoluminescent mixture (white color) in ultra-pure water (FIG. 8B) or in ultra-pure electromagnetized water (FIG. 8C). Following drop evaporation, the water structuration was observed with epifluorescence microscopy with magnification X40 after blue light exposure at 482 nm. Scale bar = 20 pm.

[0025] FIG. 9A shows grayscale luminosity evaluated on several areas of the face (white outlines) before and after exposure to blue light (405 nm). Pictures illustrate the emission of light at 560 nm. FIG. 9B shows average percentage ± standard deviation of grayscale luminosity at 560 nm on defined areas immediately or 10 min after application of the exemplary Clinical Test Mix (see, Example 4, Table E4; dark bar) or Placebo (light bar) under exposure to blue light. The results were normalized to 100% of the area exposed to white light (Before). Statistical significance was assessed using a two-way Anova test (*p<0.05; **p<0.01).

[0026] FIGS. 10A-10F are bar graphs comparing various skin conditions in healthy volunteers who applied twice a day (morning and evening) either an exemplary Clinical Test Mix or Clinical Placebo (C. Test Mix or C. Placebo; see, Example 4, Table E4) and spent at least 6 hours daily in front of screens emitting blue light. FIG. 10A shows the color of undereye dark circles as ITA°. FIG. 10B shows anti-oxidative potential. FIG. 10C shows skin glossiness. FIG. 10D shows skin redness. FIG. 10E shows the volume of wrinkles. FIG. 10F shows skin roughness. All evaluations were conducted on day 28 of application and the values were normalized to 100% of the value at Day 0. Significance thresholds **p<0.01, ***p< 0.001, ****p<0.0001, *****p<0.00001 using the Mann- Whitney test.

[0027] FIGS. 11 A- 11C compare measures of well-being in healthy volunteers who applied twice a day (morning and evening) either an exemplary Clinical Test Mix or Clinical Placebo (C. Test Mix or C. Placebo; see, Example 4, Table E4) and spent at least 6 hours daily in front of screens emitting blue light. At day 28, stress (FIG. 11 A), energy of each chakra (FIG. 11B) and the global energy of chakra (FIG. 11C) were evaluated by measurement of the energetic field of the volunteers. The values were normalized to 100% of the value at Day 0. Significance thresholds ****p<0.0001, *****p<0.00001 using the Mann-Whitney test.

DETAILED DESCRIPTION OF THE INVENTION

[0028] Sunlight is an energy source that enables various chemical reactions in the living world, and its absorption at varying wavelengths produces a wide range of molecules essential for biological function in plants and animals. Many living beings, from bacteria to insects, sharks, and birds, can light up and glow in the dark. These biofluorescent animals absorb short-wavelength electromagnetic radiation and re-emit it at longer wavelengths, resulting in a bright fluorescent glow. This phenomenon, promoting communication, is based on several types of proteins, pigments, metabolites and chemical reactions.

[0029] Humans do not photosynthesize, however human skin is the organ that interacts most with ambient light, some of which is able to penetrate some or all layers of the skin depending on its wavelength. Visible light is the medium used to improve the appearance of the skin through rejuvenation, anti-aging, anti-oily or acne-prone skin, as well as through effects on pigmentation or skin lightening, dandruff and other skin disorders related to Malassezia, and more. The use of light as therapy is based on photobiomodulation which modulates chromophores in the skin and activates their biological activities. Retinal photoreceptors, called opsin, have been shown to be present as photosensors in the skin. Opsins are a large group of light-sensitive G protein-coupled receptors (GPCRs) whose activation triggers excitation wavelength-dependent signaling cascades. Thus, the expression of these skin photoreceptors reflects the wavelength to which the skin is exposed. [0030] Electromagnetic radiation from the sun is the main source of visible light exposure on our skin, but not the only one. Artificial light sources, such as light-emitting diodes (LEDs), flash lamps, computers, televisions, and mobile phones, e.g., smartphones, are also sources of visible light. Unlike the sun, which emits a balanced visible light spectrum called white light, artificial light sources, such as, but not limited, to digital screens from computers and smartphones, emit an unbalanced light with an intense peak in the blue light range. These and other sources of unbalanced light, are generally referred to herein as non-uniform light-emitting sources. While white light has beneficial effects on the skin and well-being of a subject (human subject), artificial light is associated with biological skin perturbation. Examples of such perturbations include, but are not limited to, skin wrinkles, dark undereye circles, oxidative stress, photodamage, photoaging, and rough, red, dull, and inflamed skin. Exposure to non-uniform light-emitting sources may also impact, for example, a subject’s emotional stress levels, energy levels, and circadian rhythm, which can negatively affect their sense of well-being. Despite this, adults spend about 11 hours per day in front of a screen. In addition, many use other non-uniform light-emitting devices simultaneously (second screening).

[0031] Unbalanced visible light can be modulated by means of fluorescence mechanisms. Modulation strategies typically focus on absorbing harmful light to decrease the intensity of harmful light received by a subject. However, these strategies fail to transform the harmful light into a more balanced beneficial light by reemitting the energy at higher wavelengths. The compositions, e.g., light-modulating cosmetic compositions and consumer products containing such compositions, provided herein, use light emitted from non-uniform light-emitting sources, as an energy source and transform the non-uniform light into a more balanced mix of wavelengths, e.g., white light. The compositions provided herein are advantageous in their ability to simultaneously protect the skin from harmful wavelengths and provide skin wellness benefits. Another advantage of the compositions provided herein is their commercial cosmetic usability. For example, the compositions provided herein may be used as cosmetic consumer products without the need to undergo therapeutic treatment.

[0032] Thus, provided herein are light-modulating cosmetic compositions and consumer products containing light-modulating cosmetic compositions. Also provided are methods and uses of such light-modulating cosmetic compositions and consumer products. In aspects are provided methods of making consumer products containing light-modulating cosmetic compositions and kits containing light-modulating cosmetic compositions.

[0033] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0034] This disclosure is not limited by the exemplary methods and materials disclosed herein, and any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of this disclosure.

[0035] The headings provided herein are not limitations of the various aspects or embodiments of this disclosure which can be had by reference to the specification as a whole. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. Any terms defined are more fully defined by reference to the specification as a whole.

[0036] All publications, including patent documents, scientific articles and databases, referred to in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication were individually incorporated by reference. Nothing herein is to be construed as an admission that such publications constitute prior art. If a definition set forth herein is contrary to or otherwise inconsistent with a definition set forth in the patents, applications, published applications and other publications that are herein incorporated by reference, the definition set forth herein prevails over the definition that is incorporated herein by reference.

[0037] All of the features disclosed in this specification may be combined in any combination. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.

Definitions

[0038] Definitions of terms may appear throughout the specification. It is to be understood that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. [0039] Tt must be noted that as used herein and in the appended claims, the singular forms "a", "an", and “the” include plural referents unless the context clearly dictates otherwise. For example, “a” or “an” include “at least one” and “one or more.”

[0040] The terms "comprising", "comprises" and "comprised of’ as used herein are synonymous with "including", "includes", "containing", "contains", and grammatical variants thereof, are inclusive or open-ended and do not exclude additional, non-recited members, elements or method steps. The terms "comprising", "comprises" and "comprised of”, "including", "includes" or "containing", "contains", and grammatical variants thereof also include the term "consisting of’.

[0041] The term “skin” and grammatical variants thereof refer to any part of the skin of the human body, including the skin of the face, including the lips and eyelids, undereye skin, the neck, the scalp, and the skin of the hands. In some embodiments, the target tissue described herein is the skin at the level of the face, including the eye contour and the contour of the lips, and at the level of the neck.

[0042] “Prevent”, “preventing”, “prevention”, “inhibit”, “inhibiting”, “inhibition” and grammatical variants thereof mean delaying or preventing the appearance of a sign, an effect, or a condition. "Reducing", “reduction”, and grammatical variants referred to in terms of the methods and uses described herein mean decreasing, attenuating, fading, correcting or slowing down the development of said sign, effect, or condition. In some embodiments, a reduction in any sign, effect, or condition described herein, e.g., skin condition, condition of well-being, includes decreases of about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, inclusive of all values falling in between these percentages, in expression of the sign, effect, or condition prior to use of a composition described herein. In some embodiments, a reduction in any sign, effect, or condition described herein, e.g., skin condition, condition of well-being, includes decreases of about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, inclusive of all values falling in between these percentages, in expression of the sign, effect, or condition relative to a subject having a sign, effect, or condition and not administered a composition described herein. In some embodiments, the sign, effect or condition is an adverse effect described herein. In some embodiments, a beneficial effect as described herein is the preventing or inhibiting of an adverse effect described herein. [0043] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within this disclosure. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within this disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in this disclosure.

[0044] Values and ranges may be presented herein with numerical values being preceded by the term "about." The term "about" is used herein to provide literal support for the exact number that it precedes as well as a number that is near to or approximately the number that the term precedes. In determining whether a number is near to or approximately a specifically recited number, the near or approximating unrecited number can be a number which, in the context in which it is presented, provides the substantial equivalent of the specifically recited number. For example, in connection with a numerical value, the term “about” refers to a range of -10% to +10% of the numerical value, unless the term is otherwise specifically defined in context. All values and ranges may implicitly include the term “about” unless the context dictates otherwise.

[0045] As used herein, the term "consumer" means both the user of the cosmetic composition or consumer product and the observer nearby or around the user.

[0046] The abbreviations used herein have their conventional meaning within the chemical, physical, and biological arts.

I. LIGHT-MODULATING COSMETIC COMPOSITIONS AND CONSUMER PRODUCTS THEREOF

[0047] Provided herein are cosmetic compositions having light-modulating activity, which are generally referred to herein as light-modulating cosmetic compositions. The light-modulating cosmetic compositions described herein modulate light from non-uniform light-emitting sources having emission profiles showing high intensity peaks in one or more wavelengths or bands of wavelengths known to have adverse effects on tissue, e.g., human tissue such as skin, hair, and nails, and/or subject well-being to convert the non-uniform light emitted from the source into a light with beneficial effects. In some embodiments, the adverse effect is or includes photodamagc, photoaging, aging, oxidative stress, redness, wrinkles, fine lines, dark undereye circles, emotional stress, and/or low chakra energy. In some embodiments, the adverse effect is or includes photodamage, photoaging, aging, oxidative stress, redness, wrinkles, fine lines, dark undereye circles, or roughness of a tissue exposed to a non-uniform light-emitting source. In some embodiments, the adverse effect is or includes emotional stress or low chakra energy. Thus, in an aspect is provided a light-modulating cosmetic composition containing one or more photoluminescent compounds, for example as described in Section I-A below, that modulate an irradiance of a non-uniform light-emitting source on a target tissue. The irradiance may be referred to as a spectral irradiance. The target tissue is a tissue that is exposed to the non-uniform light source. In some embodiments, the subject is a human. In some embodiments, the target tissue is a human tissue. In some embodiments, the target tissue is skin, hair, and/or nails. In some embodiments, the target tissue is skin. In some embodiments, the target tissue is facial skin. In some embodiments, the target tissue is undereye skin. In some embodiments, the target tissue is hair, hr some embodiments, the target tissue is nails.

[0048] In some embodiments, the light-modulating cosmetic composition modulates an intensity of light in one or more of an ultraviolet spectrum, a visible spectrum, or an infrared spectrum emitted by a non-uniform light-emitting source. In some embodiments, the modulation includes independently increasing, decreasing, or maintaining the intensity of the light. For example, in some embodiments, the light-modulating cosmetic composition decreases high intensity emission wavelength peaks, increases emission wavelengths with intensities lower than the peak emission wavelengths, and maintains intensities of wavelengths with emission peaks between the high and low intensity emission wavelengths. Thus, in some embodiments, the light-modulating cosmetic composition independently modulates the intensity of different wavelengths from the non-uniform light-emitting source to produce an emission profile with balanced light. In some embodiments, the balanced light includes a mixture of wavelengths with equal or about equal intensities. In some embodiments, the balanced light includes a mixture of wavelengths where the emission profile does not have intense peaks. For example, the emission peak intensities differ by less than 20, 15, 10, 5, or 1%. In some embodiments, the modulation of intensity is determined by measuring irradiance (spectral irradiance). In some embodiments, the light-modulating cosmetic composition may modulate an emission profile of a non-uniform light-emitting source to produce a white light. In some embodiments, the light-modulating cosmetic composition modulates the irradiance of the non-uniform light-emitting source to produce a white light. In this way, for example, the lightmodulating cosmetic composition converts non-uniform light including peak emissions in wavelengths, or bands of wavelengths, with known adverse effects from a non-uniform lightemitting source into light having an emission profile with a beneficial effect. In some embodiments, the emission profile is or includes the visible light spectrum.

[0049] In some embodiments, the beneficial effect is or includes reducing or preventing photodamage, photoaging, aging, oxidative stress, redness, wrinkles, fine lines, dark undereye circles, and roughness of a target tissue. In some embodiments, the beneficial effect is or includes maintaining or improving glossiness, brightness, or smoothness of a target tissue. In some embodiments, the target tissue is tissue exposed to non-uniform light-emitting sources. The target tissue may be any tissue described herein. In some embodiments, the beneficial effect is or includes improving or maintaining the well-being of a subject, e.g., human subject. In some embodiments, the well-being is or includes decreasing emotional stress and/or increasing chakra energy. Beneficial effects may be determined by comparing measures made prior to use of the lightmodulating cosmetic composition, or a consumer product containing the light-modulating cosmetic composition, for example consumer products described in Section I-B, and after use. For example, a comparison may be made after 1, 2, 3, 4, 5, 6 days, 1, 2, 3 weeks, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 months, or one or more years after use, for example continuous, intermittent, or cyclic use. Beneficial effects may also be determined by comparing against subjects exposed to identical conditions but who do not use a light-modulating cosmetic composition or consumer product described herein. Non-limiting methods of assessing beneficial effects are described in Sections II and V below.

[0050] The light-modulating cosmetic compositions described herein are contemplated as useful for modulating light intensities, and irradiance, of light emitted from non-uniform light-emitting sources. As described above, a non-uniform light-emitting source includes light sources having emission profiles with high intensity peaks in one or more wavelengths or bands of wavelengths known to have adverse effects on tissue, e.g., human tissue such as skin, hair, and nails, and/or subject well-being. This type of emission profile may alternatively be referred to herein as unbalanced. By unbalanced is meant light that does not contain a mixture of wavelengths with equal or about equal intensities, and which includes high intensity peaks in one or more wavelengths or bands of wavelengths known to have adverse effects on tissue, c.g., human tissue such as skin, hair, and nails, and/or subject well-being. It should be appreciated that a non-uniform light-emitting source may be a light source that emits a single wavelength or narrow band of wavelengths (e.g., ±20, 10, 5 nm). In some embodiments, the single wavelength or narrow band of wavelengths is known to have adverse effects on tissue, e.g., human tissue such as skin, hair, and nails, and/or subject well-being.

[0051] In some embodiments, the non-uniform light-emitting source is an artificial light source. Examples of artificial light sources that are non-uniform light-emitting sources include, but are not limited to, computers such as desktop computers, laptop computers, and tablets; mobile phones (cell phones) such as smartphones; televisions; VR/AR devices; fluorescent lights; and LEDs, and components thereof, e.g., a screen, that emits non-uniform light. In some embodiments, the non- uniform light-emitting source is a computer, e.g., desktop computer, laptop computer, tablet. In some embodiments, the non-uniform light-emitting source is a tablet. In some embodiments, the non-uniform light-emitting source is a mobile phone. In some embodiments, the non-uniform light-emitting source is a mobile phone that is a smartphone. In some embodiments, the non- uniform light-emitting source is a smartphone. In some embodiments, the non-uniform lightemitting source is a television. In some embodiments, the component is a screen, e.g., computer screen, tablet screen, television screen, mobile phone screen. In some embodiments, the non- uniform light-emitting source is a light source that emits at least one non-uniform emission wavelength in the blue light spectrum. For example, the non-uniform light-emitting source is a light source having a peak emission in the blue light spectrum. In some embodiments, the non- uniform light-emitting source contains a peak emission in a wavelength in the blue light spectrum.

A. Light-modulating cosmetic compositions

[0052] The light-modulating cosmetic compositions having the features described herein include photoluminescent compounds with the ability to modulate light intensities and irradiance, e.g., on a target tissue, from a non-uniform light-emitting source. In some embodiments, the photoluminescent compounds modulate the intensity of light in one or more of an ultraviolet spectrum, a visible spectrum, or an infrared spectrum emitted by a non-uniform light-emitting source. In some embodiments, the modulation includes independently increasing, decreasing, or maintaining the intensity of the light. Tn some embodiments, the modulation includes balancing light intensities from a non-uniform light-emitting source to produce a mixture of wavelengths with equal or about equal intensities. In some embodiments, the mixture of wavelengths with equal or about equal intensities is white light. In some embodiments, the photoluminescent compounds modulate the irradiance of the non-uniform light-emitting source to produce a white light, e.g., on a target tissue. In some embodiments, the light-modulating cosmetic composition includes one or more photoluminescent compounds, where the compounds modulate the same or different wavelengths of light. In some embodiments, each of the one or more compounds acts independently to increase, decrease, or maintain the intensity of a wavelength or band of wavelengths of light. For example, one photoluminescent compound may decrease the intensity of light while another compound may increase a different light intensity. In some embodiments, a photoluminescent compound in the light-modulating cosmetic composition may maintain a light intensity either by not interacting with the wavelength or preventing a loss of intensity. In some cases, two or more compounds modulate light of the same wavelength or band of wavelengths. For example, two or more compounds modulate blue light. In some cases, two or more compounds modulate light of different wavelengths or band of wavelengths. For example, one compound of the two or more compounds modulates blue light and a different compound modulates red light.

[0053] In some embodiments, the light-modulating cosmetic composition includes at least 2 different photoluminescent compounds. In some embodiments, at least one compound has an absorption peak wavelength in a range of about 380 to about 500 nm. In some embodiments, each compound has at least one absorption peak wavelength in a range of about 380 to about 500 nm. In some embodiments, at least one compound has an emission peak wavelength in a range of about 500 to about 575 nm. In some embodiments, at least one other compound has an emission peak wavelength in a range of about 575 to about 780 nm. In some embodiments, at least one compound has an emission peak wavelength in a range of about 575 to about 780 nm. In some embodiments, the light-modulating cosmetic composition includes at least 3 different photoluminescent compounds. In some embodiments, the light-modulating cosmetic composition includes at least one photoluminescent compound having an emission peak wavelength in a range of about 400 to about 500 nm.

[0054] In some embodiments, the photoluminescent compounds include organic pigments. In some embodiments, the photoluminescent compounds include inorganic pigments. In some embodiments, the photoluminescent compounds include organic pigments and inorganic pigments.

[0055] In some embodiments, at least one compound having an emission peak wavelength in a range of about 500 to about 575 nm is selected from Octahydrocoumarin, Fluorescein, Eosin Y, Tartazine, 2h-l-benzopyran-2-one, Daphnetin, Coumarin, 7-Diethylamino-4-methylcoumarin, Quinoline, Scoparone, Curcurmine, and Naphthalimide. In some embodiments, at least one compound having an emission peak wavelength in a range of about 500 to about 575 nm is selected from Fluorescein and Eosin Y. In some embodiments, at least one other compound having an emission peak wavelength in a range of about 575 to about 780 nm is selected from Phloxine, Rhodamine B, Rhodamine 6G, Benzopyran, and Cyanine. In some embodiments, at least one other compound having an emission peak wavelength in a range of about 575 to about 780 nm is selected from Phloxine and Rhodamine B. In some embodiments, the light-modulating cosmetic composition includes at least one compound having an emission peak wavelength in a range of about 400 to about 500 nm selected from coumarin, aminocoumarin, and a disulphonic acid stilbene derivative. In some embodiments, the light-modulating cosmetic composition includes Fluorescein, Eosin Y, and Phloxine. In some embodiments, the light-modulating cosmetic composition includes Fluorescein, Eosin Y, CI47005, and Phloxine,

[0056] In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is at least about 0.001 , 0.005, 0.01 , 0.05, 0.1 , 0.5, 1 , 2, 3, 4, 5, 10, 15, 20, 30, 40, or 50% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is at least about 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 2, 3, 4, 5, 10, 15 or 20% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the lightmodulating cosmetic composition is at least about 0.001, 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 10 or 15% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is at least about 0.001, 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, or 10% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is at least about 0.001, 0.01, 0.1, 0.5, 1, 2, 3, 4, or 5% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 50% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 40% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 30% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 20% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 15% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 10% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 5% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 2% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 1% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 0.5% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 0.1% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 0.01% weight of the composition.

[0057] In some embodiments, the light-modulating cosmetic composition includes a first photoluminescent compound that comprises about 50% to about 100% of the total amount of photoluminescent compounds in the composition. In some embodiments, the light-modulating cosmetic composition includes a second photoluminescent compound that comprises about 0.0001% to about 15% of the total amount of photoluminescent compounds in the composition. In some embodiments, the light-modulating cosmetic composition includes a third photoluminescent compound that comprises about 0.0001 % to about 15% of the total amount of photoluminescent compounds in the composition. [0058] Tn some embodiments, the light-modulating cosmetic composition includes a first and a second photolumincsccnt compound at a ratio of 8:1. In some embodiments, the light-modulating cosmetic composition includes a first, a second, and a third photoluminescent compound at a ratio of 8:1:1. In some embodiments, the light-modulating cosmetic composition includes a first, a second, a third, and a fourth photoluminescent compound at a ratio of 5: 1:1:1.

[0059] In some embodiments, the light-modulating cosmetic composition decreases an irradiance of blue light from the non-uniform light-emitting source. In some embodiments, the lightmodulating cosmetic composition emits an orange light. For example, the light-modulating cosmetic composition increases the irradiance of an orange light. In some embodiments, the lightmodulating cosmetic composition decreases an irradiance of blue light from the non-uniform lightemitting source and emits an orange light, e.g., increases the irradiance of the orange light. In some embodiments, the blue light is in the range of about 450 nm ± about 50 nm. In some embodiments, the blue light is in the range of about 450 nm ± about 25 nm. In some embodiments, the orange light is in the range of about 600 nm ± about 50 nm. In some embodiments, the orange light is in the range of about 600 nm ± about 25 nm. In some embodiments, the decrease in blue light irradiance is at least about 1, 2, 3, 4, 5, 10, 15, 20, 30, 40, or 50% compared to the unmodulated irradiance. In some embodiments, the decrease in blue light irradiance is in the range of about 1% to about 50% compared to the unmodulated irradiance. In some embodiments, the decrease in blue light irradiance is in the range of about 1% to about 40% compared to the unmodulated irradiance. In some embodiments, the decrease in blue light irradiance is in the range of about 1% to about 30% compared to the unmodulated irradiance. In some embodiments, the decrease in blue light irradiance is in the range of about 1% to about 20% compared to the unmodulated irradiance. In some embodiments, the decrease in blue light irradiance is in the range of about 1% to about 15% compared to the unmodulated irradiance. In some embodiments, the decrease in blue light irradiance is in the range of about 1% to about 10% compared to the unmodulated irradiance. In some embodiments, the decrease in blue light irradiance is in the range of about 1% to about 5% compared to the unmodulated irradiance. In some embodiments, the increase in orange light emission intensity is at least about 1, 2, 3, 4, 5, 10, 15, 20, 30, 40, or 50% compared to the unmodulated emission. Tn some embodiments, the increase in orange light emission intensity is at least about 1, 2, 3, 4, 5, 10, 15, 20, 30, or 40% compared to the unmodulated emission. In some embodiments, the increase in orange light emission intensity is at least about 1, 2, 3, 4, 5, 10, 15, 20, or 30% compared to the unmodulated emission. Tn some embodiments, the increase in orange light emission intensity is at least about 1, 2, 3, 4, 5, 10, 15, or 20% compared to the unmodulated emission. In some embodiments, the increase in orange light irradiance is in the range of about 1% to about 50% compared to the unmodulated irradiance. In some embodiments, the increase in orange light irradiance is in the range of about 1% to about 40% compared to the unmodulated irradiance. In some embodiments, the increase in orange light irradiance is in the range of about 1% to about 30% compared to the unmodulated irradiance. In some embodiments, the increase in orange light irradiance is in the range of about 1% to about 20% compared to the unmodulated irradiance. In some embodiments, the increase in orange light irradiance is in the range of about 1% to about 15% compared to the unmodulated irradiance. In some embodiments, the increase in orange light irradiance is in the range of about 1% to about 10% compared to the unmodulated irradiance. In some embodiments, the light-modulating cosmetic composition does not change (e.g., maintains) an irradiance of a wavelength at about 540 nm. For example, in some embodiments, the change in irradiance of a wavelength at about 540 nm is less than 5, 4, 3, 2, or 1 % compared to the unmodulated irradiance.

[0060] In some embodiments, the light-modulating cosmetic composition includes one or more of glycerin, water (e.g., deionized water), a glycol derivative, a hydrogel, or other solvent or powder carrier acceptable for topical application. In some embodiments, the light-modulating cosmetic composition includes glycerin. In some embodiments, the light-modulating cosmetic composition includes glycerin and a hydrogel. In some embodiments, the light-modulating cosmetic composition includes one or more of glycerin, an acrylate (e.g., C10-30 alkyl acrylate cross-polymer), xanthum gum, or triglycerides (e.g., medium chain triglycerides). In some embodiments, the light-modulating cosmetic composition includes one or more of an emollient, a humectant, a gelling agent, an emulsifier, an oil, a wax, a preservative, a fragrance, an active ingredient, a pigment, a sunscreen, a colorant, a chelatant, or an antioxidant. In some embodiments, the light-modulating cosmetic composition includes a gelling agent.

[0061] In some embodiments, the light-modulating cosmetic composition includes one or more of glyceryl stearate, PEG (e.g., PEG- 100 strearate), isononyl isononanoate, mineral oil, dimethicone, phenoxyethanol, methylparaben, ethylparaben, butylparaben, propylparaben, water, or sodium hydroxide. In some embodiments, the light-modulating cosmetic composition includes one or more of water, sodium phytate, alcohol, xanthan gum, C12-C16 alcohols, hydrogenated lecithin, palmitic acid, isoamyl laurate, shorea stenoptera seed butter, diisopropyl adipate, shea butter cetyl esters, behenyl alcohol, butyrospermum parkii (shea) butter unsaponifiablcs, soybean glycerides, macadamia ternifolia seed oil, dimethicone, fragrance, helianthus annuus (sunflower) seed oil, tocopherol, phenoxyethanol or caprylyl glycol.

[0062] In some embodiments, the light-modulating cosmetic composition includes one or more active agents with cosmetic effects. An active ingredient with cosmetic effect, active agent with cosmetic effect, cosmetic agent, or active ingredient with cosmetic effect refers to a compound capable of exerting at least one cosmetic effect on the skin, the hair, and/or nails. A cosmetic effect means any non-therapeutic effect aimed at modifying and/or improving the visual appearance and mechanical properties of the skin, hair, and/or nails, e.g., protecting them from external aggressions (sun, wind, humidity, dryness, chemicals), preventing and/or correcting phenomena related to their aging, or preventing or treating the effects caused by stress or fatigue, inflammation. In some embodiments, the light-modulating cosmetic composition exerts a cosmetic effect independent of the additional active agents that have cosmetic effects.

[0063] Examples of such agents include, among others, anti-wrinkle agents, anti-aging agents, antioxidant agents, anti-inflammatory agents, anti-stress agents, moisturizing agents, soothing agents, anti-redness agents, decongestant agents, exfoliants or exfoliating agents, matting agents, seboregulating agents, lightening active ingredients, anti-stain active ingredients, anti-dark undereye circle or anti-undereye bag agents, anti-stress agents, anti-fatigue agents, anti-pollution active ingredients, tensor agents, filters and sunscreens, and combinations thereof.

[0064] In some embodiments, the light-modulating cosmetic composition may include an active ingredient selected from an anti-wrinkle agent, an anti-redness agent, an antioxidant agent, a moisturizing active ingredient, a soothing agent, a seboregulating agent, an anti- stain or lightening agent, a tensor agent, an anti-pollution active ingredient, anti-dark undereye circle or anti-undereye bag agents, a filter or sunscreen, and combinations thereof.

[0065] A non-limiting example of anti-pollution agents includes extracts of Chrysanthellum Indicum polysaccharides, e.g., from a fermentation medium of Alteromonas and salts of Nigari.

[0066] Non-limiting examples of anti-undereye bag agents includes extracts of Chrysantellum Indicum or sulfated polysaccharides of algae, in particular Ofcophyllum nodosum or Asparagopsis Armata. [0067] Non-limiting examples of moisturizing agents include urea, pidolic acid (PCA) and its derivatives in particular its salts such as arginine PCA, chitosan PCA, its salts of copper (Copper PCA), magnesium (magnesium PCA), sodium (sodium PCA) or zinc, ethylhexyl PCA, calcium gluconate, hyaluronic acid and its salts and other glycosaminoglycans, frucosis, glucose, isomaltose, lactose, trehalose, polydextrose, sucrose (Sucrose), maltitol, mannitol, sorbitol, xylitol and other carbohydrates and derivatives, polyethylene glycols such as PEG-7, PEG-8, PEG- 10, PEG- 12 or PEG- 14, glycerin, propylene glycol, butylene glycol, betaine, citrulline, collagen and its derivatives, histidine, silk, keratin or soy hydrolysates, plant extracts rich in polysaccharides and / or polyphenols, for example extracts of Aloe, blueberry (Cenlaurea cyanus), extracts rich in polysaccharides, in particular from fermentation media of marine microorganisms such as Alteromonas and combinations thereof.

[0068] Non-limiting examples of anti-aging agents include ascorbic acid and its derivatives such as magnesium ascorbyl phosphate, glycosaminoglycans and their derivatives, Cyathea polysaccharides, collagen, flaxseed extracts (Linum usitatissimum), peptides such as Caprooyl- Tetrapeptide-3 and trifluoroacetyl tripeptide-2, extracts of Polygonum aviculare. extracts of brown algae, in particular Ascophyllum nodosum, extracts of fems, especially Cyathea cumingii.

[0069] Non-limiting examples of anti-stress agents include Rosality™ products (a combination of rose water and rose essential oil) and rose cistus extract, for example marketed under the brand name IBR-Chill™.

[0070] Non-limiting examples of soothing agents include allantoin, extracts of aloe, birch (e.g. Betula alba), fireweed (Epilobium angustifolium), chestnut (e.g. Castenea sativa), blueberry (e.g. Centaurea cyanus), centella (e.g. Centella asiatica), horsetail (e.g. Equisetum arvense), fennel (e.g. Foeniculum vulgare ), witch hazel (e.g. Hamamelis virginiana), ivy (e.g. Hedera helix), habiscus sabdariffa, lily (e.g. Lilium candidum), mallow (e.g. Malva sylvestris), lemon balm (e.g. Melissa officinalis), skullcap (e.g. Scutellaria baicalensis), mimosa (e.g. Mimosa tenuiflora), potentilla (e.g. Potentilla erecta), an extract of oligosaccharides or an oligosaccharide, e.g. flax, peptides such as palmitoyl tripeptide-8, extracts of polysaccharides, including extracts of exopolysaccharides from the fermentation medium of Alteromonas and combinations thereof.

[0071] Non-limiting examples of antioxidant agents include HMR (hydroxy methyl resorcinol), ascorbic acid and its derivatives, vitamin B9, histidine hydrochloride, or a fireweed extract (Epilobium augustifolium). Active ingredients with antioxidant and vitamin-like effect are usually used in a mass percentage of at least 1% of the total weight of the cosmetic composition.

[0072] Non-limiting examples of seboregulatory agents include flax lignans, rice powder, zinc gluconate, sarcosine, an extract of Cinnamomum zeylanicum bark, an extract of avocado, an extract of Backhousia citriodora and combinations thereof.

[0073] Non-limiting examples of anti-redness agents include saponins, flavonoids, ruscogenins, esculosides, and extracts containing them, for example extracts of Rus cus, as well as certain essential oils, for example lavender or rosemary.

[0074] Non-limiting examples of anti-stain agents include extracts such as licorice (Glycyrrhyza glabra), jackfruit extract (Artocarpus heterophyllus), Rumcx extract (R.occidentalis), plant extracts belonging to the genus citrus, resveratrol, peptides such as oligopep tide-68, nonapeptide- 1, kojic acid, magnesium ascorbyl phosphate and combinations thereof.

[0075] In some embodiments, the light-modulating cosmetic composition is contained in a cream, a lotion, a gel, a foam, a paste, a salve, a balm, a varnish, or an ointment. In some embodiments, the total concentration of photoluminescent compounds contained in the cream, the lotion, the gel, the foam, the paste, the salve, the balm, the varnish, or the ointment is at least about 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, or 1% weight. In some embodiments, the total concentration of photoluminescent compounds contained in the cream, the lotion, the gel, the foam, the paste, the salve, the balm, the varnish, or the ointment is in a range of about 0.001% to about 1% weight. In some embodiments, the total concentration of photoluminescent compounds contained in the cream, the lotion, the gel, the foam, the paste, the salve, the balm, the varnish, or the ointment is in a range of about 0.001% to about 0.5% weight. In some embodiments, the total concentration of photoluminescent compounds contained in the cream, the lotion, the gel, the foam, the paste, the salve, the balm, the varnish, or the ointment is in a range of about 0.001 % to about 0.1% weight. In some embodiments, the total concentration of photoluminescent compounds contained in the cream, the lotion, the gel, the foam, the paste, the salve, the balm, the varnish, or the ointment is in a range of about 0.001% to about 0.05% weight. In some embodiments, the total concentration of photoluminescent compounds contained in the cream, the lotion, the gel, the foam, the paste, the salve, the balm, the varnish, or the ointment is in a range of about 0.001% to about 0.01% weight. In some embodiments, the total concentration of photoluminescent compounds contained in the cream, the lotion, the gel, the foam, the paste, the salve, the balm, the varnish, or the ointment is in a range of about 0.001% to about 0.005% weight. It is understood that the percent weight is with respect to the weight of the composition.

[0076] In some embodiments, the light-modulating cosmetic composition modulates the irradiance of the non-uniform light-emitting source on the target tissue for at least about 1, 2, 3, 4, 5, 6, 7, 8, or more hours.

B. Consumer Products

[0077] The light-modulating cosmetic compositions described herein may be contained in a consumer product. As used herein, a consumer product may be a facial or body powder, a foundation, a make-up product, an oil (c.g., body oil, facial oil), a mousse, a cream, a wax, a balm (e.g., lip balm), a mask, a paste, a foam, a salve, a gel, a varnish, an ointment, a lotion (e.g., a body lotion, facial lotion), a spray, a personal care product, a nail care product, a baby care product, a non-aerosol body spray, a body milk, a body cream, a sunscreen lotion, a sunscreen spray, a sun block, a roll-on product, an aerosol product, a natural spray product, a hair care product, a fabric care product, and the like.

[0078] In some embodiments, the consumer product is a cream, a lotion, a gel, a foam, a paste, a salve, a balm, a varnish, or an ointment. In some embodiments, the consumer product is a cream. Tn some embodiments, the cream is an emulsion. Tn some embodiments, the consumer product is a lotion. In some embodiments, the consumer product is a varnish.

[0079] In some embodiments, the consumer product is a personal care product, a skin care product, a body care product, a hair care product, a make-up product, a nail care product, or a baby care product. In some embodiments, the consumer product is a skin care product. In some embodiments, the consumer product is a body care product. In some embodiments, the consumer product is a nail care product. In some embodiments, the consumer product is a baby care product.

[0080] In some embodiments, the total concentration of photoluminescent compounds contained in the consumer product is at least about 0.001, 0.005, 0.01, 0.05, 0.1, or 0.5, or 1% weight. In some embodiments, the total concentration of photoluminescent compounds contained in the consumer product is in a range of about 0.001% to about 1% weight. In some embodiments, the total concentration of photoluminescent compounds contained in the consumer product is in a range of about 0.001 % to about 0.5% weight. In some embodiments, the total concentration of photolumincsccnt compounds contained in the consumer product is in a range of about 0.001% to about 0.1% weight. In some embodiments, the total concentration of photoluminescent compounds contained in the consumer product is in a range of about 0.001% to about 0.05% weight. In some embodiments, the total concentration of photoluminescent compounds contained in the consumer product is in a range of about 0.001% to about 0.01% weight. In some embodiments, the total concentration of photoluminescent compounds contained consumer product is in a range of about 0.001% to about 0.005% weight. It is understood that the percent weight is with respect to the weight of the consumer product.

II. COSMETIC METHODS AND USE

[0081] Also provided herein are methods and uses of light-modulating cosmetic compositions and consumer products containing light-modulating cosmetic compositions. The methods and uses provided herein include topical application of the light-modulating cosmetic composition or consumer product to provide a beneficial effect to a target tissue and/or well-being of a subject.

[0082] In an aspect is provided a method of modulating an irradiance from a non-uniform lightemitting source on a target tissue including topically applying a light-modulating cosmetic composition or consumer product described herein to a target tissue.

[0083] Tn an aspect is provided a method of reducing or preventing photodamage to a target tissue from a light emitted from a non-uniform light-emitting source, including topically applying a lightmodulating cosmetic composition or a consumer product described herein to a target tissue. In some embodiments, the photodamage includes photo-oxidative stress. In some embodiments, the photodamage includes photoaging.

[0084] In an aspect is provide a method of reducing or preventing aging of a target tissue from a light emitted from a non-uniform light-emitting source, including topically applying a lightmodulating cosmetic composition or a consumer product described herein to a target tissue.

[0085] In an aspect is provided a method of reducing or preventing oxidative stress of a target tissue from a light emitted from a non-uniform light-emitting source, including topically applying a light-modulating cosmetic composition or a consumer product described herein to a target tissue. [0086] Also provided is a method of modulating photoactivation of a chromophore in a target tissue by a light emitted from a non-uniform light-emitting source, including topically applying a light-modulating cosmetic composition or a consumer product described herein to a target tissue. In some embodiments, the chromophore is water. In some embodiments, the chromophore is an opsin. In some embodiments, the opsin is contained in a photoreceptor. In some embodiments, the photoreceptor is present in the target tissue. In some embodiments, the opsin is opsin 1SW. In some embodiments, the opsin is opsin 2. In some embodiments, the opsin is opsin 1SW and opsin 2. In some embodiments, the chromophore is a cytochrome C oxidase (CCO). In some embodiments, the CCO is contained in a mitochondrion.

[0087] Tn some embodiments, modulating photoactivation of the chromophore includes increasing or decreasing photoactivation of the chromophore. In some embodiments, modulating photoactivation of the chromophore includes stimulating a biological response in the target tissue. In some embodiments, the biological response includes one or more of restoring or maintaining a level of activity, increasing a level of activity, or decreasing a level of activity. Restoring activity refers to reaching a level of activity observed prior to exposure, optionally repeated exposure, to a non-uniform light-emitting source. Maintaining a level of activity refers to holding a level of activity following an exposure, optionally repeated exposure, to a non-uniform light-emitting source. Increasing a level of activity refers to increasing an activity level that would have been maintained or decreased in response to exposure, optionally repeated exposure, to a non-uniform light-emitting source. Decreasing a level of activity refers to decreasing an activity level that would have been maintained or increased in response to exposure, optionally repeated exposure, to a non- uniform light-emitting source. In some embodiments, an increase in activity includes increases of at least or about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, inclusive of all values falling in between these percentages, in expression of the activity prior to use of a composition described herein. In some embodiments, an increase in an activity includes increases of at least or about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, inclusive of all values falling in between these percentages, in expression of activity relative to activity in a subject not using a composition described herein and exposed to identical conditions. Tn some embodiments, a decrease in activity includes decreases of at least or about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, inclusive of all values falling in between these percentages, in expression of the activity prior to use of a composition described herein. In some embodiments, a decrease in an activity includes decreases of at least or about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, inclusive of all values falling in between these percentages, in expression of activity relative to activity in a subject not using a composition described herein and exposed to identical conditions. In some embodiments, maintaining an activity includes no more than about a 15% change in expression of the activity prior to use of a composition described herein. In some embodiments, maintaining an activity includes no more than about a 15% change in expression of activity relative to activity in a subject not using a composition described herein and exposed to identical conditions. In some embodiments, maintaining an activity includes no more than about a 10% change in expression of the activity prior to use of a composition described herein. In some embodiments, maintaining an activity includes no more than about a 10% change in expression of activity relative to activity in a subject not using a composition described herein and exposed to identical conditions. In some embodiments, maintaining an activity includes no more than about a 5% change in expression of the activity prior to use of a composition described herein. In some embodiments, maintaining an activity includes no more than about a 5% change in expression of activity relative to activity in a subject not using a composition described herein and exposed to identical conditions.

[0088] In some embodiments, the biological response is a cellular communication activity. In some embodiments, the cellular communication activity is increased. In some embodiments, the biological response is a photoreceptor expression activity. In some embodiments, the photoreceptor expression activity is increased expression of opsin 2. In some embodiments, the photoreceptor expression activity is decreased expression of opsin 1SW. In some embodiments, the biological response is a mitochondrial activity. In some embodiments, the mitochondrial activity is maintained or restored. Methods of measuring biological activity of interest are known in the art and non-limiting examples of such methods contemplated herein are described in Section V.

[0089] In an aspect is provided a method of improving an appearance of a target tissue exposed to a light emitted from a non-uniform light-emitting source, including topically applying a lightmodulating cosmetic composition or a consumer product described herein to a target tissue. In some embodiments, the improving includes reducing or preventing a roughness of the target tissue or maintaining the smoothness of the target tissue. Tn some embodiments, the improving includes reducing or preventing wrinkles or fine lines in the target tissue. In some embodiments, the target tissue is undereye skin and the improving includes reducing the appearance of dark circles in the target tissue. In some embodiments, the improving includes reducing or preventing a redness of the target tissue. Redness may be a sign of inflammation in tissue. Thus, in some cases, the improving includes reducing or preventing an inflammatory response in the target tissue. In some embodiments, the improving includes increasing or maintaining a glossiness and/or brightness of the target tissue. Maintaining refers to holding a level of activity or condition following an exposure or repeated exposure to a non-uniform light-emitting source as described above. Increasing refers to increasing an activity level or condition that would have been maintained or decreased in response to exposure to a non-uniform light-emitting source as described above.

[0090] In an aspect is provided a method of improving a well-being of a subject exposed a light emitted from a non-uniform light-emitting source, including topically applying a light-modulating cosmetic composition or a consumer product described herein to a target tissue. In some embodiments, the improving comprises decreasing an emotional stress level, for example compared to a level of emotional stress recorded prior to the use or compared to a level of emotional stress that may be reached if use had not occurred. In some embodiments, the improving comprises increasing chakra energy, for example compared to a level of energy recorded prior to the use or compared to a level of energy that may be reached if use had not occurred. Methods of assessing stress and chakra energy levels are known in the art, and non-limiting examples of such methods are described in Section V. Levels and measures for determining an increase, decrease, or maintenance are as described above.

[0091] The target tissue described herein may be any human tissue. In some embodiments, the target tissue is any tissue exposed to non-uniform light-emitting sources. In some embodiments, the target tissue is skin. In some embodiments, the target tissue is facial skin. In some embodiments, the target tissue is undereye skin. In some embodiments, the target tissue is hair. In some embodiments, the target tissue is nails.

[0092] The dose of light-modulating cosmetic composition or consumer product to be administered and the frequency of administration vary according to the desired cosmetic effect, the characteristics of the individual, such as sex, age, hair type, and skin type. In some embodiments, the light-modulating cosmetic composition or consumer product can be applied to the area to be treated once a day, twice a day (c.g., morning and night), for several consecutive weeks or even months, for example for at least 3, 6, 9 months. For example, the subject can apply a dose of 1 g to 2 g of cosmetic composition or consumer product to his face in the evening or morning and evening.

III. METHODS OF MAKING A CONSUMER PRODUCT

[0093] In an aspect is provided a method of making a consumer product, such as a consumer product described in Section I-B, including adding to a cosmetic base a light- modulating cosmetic composition described herein to form a mixture, and (b) stirring the mixture to achieve homogeneity. Tn some embodiments, the mixture is emulsified. Tn some embodiments, the mixture is cooled. In some embodiments, the mixture is pH adjusted.

[0094] In some embodiments, the cosmetic base includes one or more of water, emollients, humectants, gelling agents, emulsifiers, oils, waxes, butter, surfactants, preservatives, fragrance, actives ingredients, pigments, sunscreens, colorants, chelatants, or antioxidants.

[0095] In some embodiments, the method includes adding one or more of an anti-wrinkle agent, an anti-aging agent, an antioxidant agent, a moisturizing agent, a soothing agent, an anti-redness agent, a decongestant agent, an exfoliant or exfoliating agent, a matting agent, a seboregulating agent, a lightening active ingredient, an anti-stain active ingredient, an anti-dark undereye circles or an anti-undereye bags agent, an anti-stress agent, an anti-fatigue, an anti-pollution active ingredient, a tensor agent, a filter or sunscreen.

IV. KITS

[0096] Also provided are kits including the light-modulating cosmetic compositions described herein, which may further include instructions on methods of using the composition, such as uses described herein. The kits described herein may also include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for performing any methods described herein.

V. EXEMPLARY EMBODIMENTS

[0097] Among the provided embodiments are: 1. A light-modulating cosmetic composition comprising one or more photoluminescent compounds, wherein the composition modulates an irradiance of a non-uniform light-emitting source on a target tissue.

2. The light-modulating cosmetic composition of embodiment 1, wherein the composition modulates an intensity of light in one or more of an ultraviolet spectrum, a visible spectrum, or an infrared spectrum emitted by the non-uniform light-emitting source.

3. The light-modulating cosmetic composition of embodiment 2, wherein the modulation comprises, independently, increasing, decreasing, or maintaining the intensity of the light.

4. The light-modulating cosmetic composition of any one of embodiments 1 to 3, wherein the composition modulates the irradiance of the non-uniform light-emitting source to produce a white light.

5. The light-modulating cosmetic composition of any one of embodiments 1 to 4, wherein the composition comprises at least 2 different photoluminescent compounds, each compound having at least one absorption peak wavelength in a range of about 380 to about 500 nm, at least one compound having an emission peak wavelength in a range of about 500 to about 575 nm, and at least one other compound having an emission peak wavelength in a range of about 575 to about 780 nm.

6. The light-modulating cosmetic composition of any one of embodiments 1 to 5, wherein the composition comprises at least 3 different photoluminescent compounds.

7. The light-modulating cosmetic composition of any one of embodiments 1 to 6, wherein the composition comprises at least one photoluminescent compound having an emission peak wavelength in a range of about 400 to about 500 nm.

8. The light-modulating cosmetic composition of any one of embodiments 1 to 7, wherein the photoluminescent compounds are organic and/or inorganic pigments.

9. The light-modulating cosmetic composition of any one of embodiments 1 to 8, wherein:

- at least one compound having an emission peak wavelength in a range of about 500 to about 575 nm is selected from Octahydrocoumarin, Fluorescein, Eosin Y, Tartazine, 2h-l-benzopyran-2-one, Daphnetin, Coumarin, 7-Diethylamino-4-methylcoumarin, Quinoline, Scoparone, Curcurmine, and Naphthalimide; and/or - at least one other compound having an emission peak wavelength in a range of about 575 to about 780 nm is selected from Phloxine, Rhodamine B, Rhodamine 6G, Benzopyran, and Cyanine.

10. The light-modulating cosmetic composition of any one of embodiments 1 to 9, wherein the composition comprises at least one compound having an emission peak wavelength in a range of about 400 to about 500 nm selected from coumarin, aminocoumarin, and a disulphonic acid stilbene derivative.

11. The light-modulating cosmetic composition of any one of embodiments 1 to 10, wherein the total concentration of photoluminescent compounds in the composition is in a range of about 0.001% to about 20% weight of the composition.

12. The light-modulating cosmetic composition of any one of embodiments 1 to 11, wherein the composition comprises a first photoluminescent compound that comprises about 50% to about 100% of the total amount of photoluminescent compounds in the composition and a second photoluminescent compound that comprises about 0.0001% to about 15% of the total amount of photoluminescent compounds in the composition.

13. The light-modulating cosmetic composition of any one of embodiments 1 to 12, wherein the composition comprises a third photoluminescent compound that comprises about 0.0001% to about 15% of the total amount of photoluminescent compounds in the composition.

14. The light-modulating cosmetic composition of any one of embodiments 1 to 13, wherein the composition comprises one or more of glycerin, water, a glycol derivative, a hydrogel, or other solvent or powder carrier acceptable for topical application.

15. The light-modulating cosmetic composition of any one of embodiments 1 to 14, wherein the composition comprises one or more of an emollient, a humectant, a gelling agent, an emulsifiers, an oil, a wax, a preservative, a fragrance, an active ingredient, a pigment, a sunscreen, a colorant, a chelatant, or an antioxidant.

16. The light-modulating cosmetic composition of any one of embodiments 1 to 15, wherein the composition is comprised in a cream, a lotion, a gel, a foam, a paste, a salve, a balm, a varnish, or an ointment. 17. The light-modulating composition of embodiment 15 or embodiment 16, wherein the total concentration of photolumincsccnt compounds in the composition is in a range of about 0.001% to about 0.1% weight.

18. The light-modulating cosmetic composition of any one of embodiments 1 to 17, wherein the composition decreases an irradiance of blue light from the non-uniform light-emitting source on the target tissue, and optionally emits an orange light.

19. The light-modulating cosmetic composition of any one of embodiments 1 to 18, wherein the non-uniform light-emitting source is one or more of a computer, a tablet, a mobile phone, a television, a fluorescent light, a light emitting diode (LED), or any other digital device or artificial light source comprising a light source that emits non-uniform light, optionally wherein at least one non-uniform emission wavelength is in the blue light spectrum.

20. The light-modulating cosmetic composition of any one of embodiments 1 to 19, wherein the composition modulates the irradiance of the non-uniform light-emitting source on the target tissue for at least about 1, 2, 3, 4, 5, 6, 7, 8, or more hours.

21. The light-modulating cosmetic composition of any one of embodiments 1 to 20, wherein the target tissue is skin, optionally facial skin, hair, and/or nails.

22. A consumer product comprising a light-modulating cosmetic composition of any one of embodiments 1 to 21, wherein the consumer product is a cream, a lotion, a gel, a foam, a paste, a salve, a balm, a varnish, or an ointment.

23. The consumer product of embodiment 22, wherein the consumer product is a skin care product, a body care product, a hair care product, a make-up product, a nail care product, or a baby care product.

24. The consumer product of embodiment 22 or embodiment 23, wherein the total concentration of photoluminescent compounds in the consumer product is in a range of about 0.001% to about 0.1% weight of the consumer product.

25. A method of modulating an irradiance from a non-uniform light-emitting source on a target tissue, comprising topically applying a light-modulating cosmetic composition of any one of embodiments 1 to 21 or a consumer product of any one of embodiments 22 to 24 to a target tissue. 26. A method of reducing or preventing photodamage to a target tissue from a light emitted from a non-uniform light-emitting source, comprising topically applying a light-modulating cosmetic composition of any one of embodiments 1 to 21 or a consumer product of any one of embodiments 22 to 24 to a target tissue.

27. The method of embodiment 26, wherein the photodamage comprises photo-induced oxidative stress.

28. The method of embodiment 26 or embodiment 27, wherein the photodamage comprises photoaging.

29. A method of reducing or preventing aging of a target tissue from a light emitted from a non- uniform light-emitting source, comprising topically applying a light-modulating cosmetic composition of any one of embodiments 1 to 21 or a consumer product of any one of embodiments 22 to 24 to a target tissue.

30. A method of reducing or preventing oxidative stress of a target tissue from a light emitted from a non-uniform light-emitting source, comprising topically applying a light-modulating cosmetic composition of any one of embodiments 1 to 21 or a consumer product of any one of embodiments 22 to 24 to a target tissue.

31. A method of modulating photoactivation of a chromophore in a target tissue by a light emitted from a non-uniform light-emitting source, comprising topically applying a light-modulating cosmetic composition of any one of embodiments 1 to 21 or a consumer product of any one of embodiments 22 to 24 to a target tissue.

32. The method of embodiment 31, wherein the chromophore comprises one or more of water, an opsin, or a cytochrome C oxidase (CCO).

33. The method of embodiment 31 or embodiment 32, wherein the chromophore is an opsin comprised in a photoreceptor, optionally wherein the opsin is opsin 1SW and/or opsin 2.

34. The method of any one of embodiments 31 to 33, wherein the chromophore is a CCO comprised in a mitochondrion.

35. The method of any one of embodiments 31 to 34, wherein the modulating photoactivation of the chromophore comprises increasing or decreasing photoactivation of the chromophore. 36. The method of any one of embodiments 1 to 35, wherein the modulating photoactivation of the chromophore comprises stimulating a biological response in the target tissue, wherein the biological response comprises one or more of restoring or maintaining a level of activity, increasing a level of activity, or decreasing a level of activity.

37. The method of embodiment 36, wherein the biological response comprises one or more of a cellular communication activity, a photoreceptor expression activity, or a mitochondrial activity.

38. A method of improving an appearance of a target tissue exposed to a light emitted from a non- uniform light-emitting source, comprising topically applying a light-modulating cosmetic composition of any one of embodiments 1 to 21 or a consumer product of any one of embodiments 22 to 24 to a target tissue.

39. The method of embodiment 38, wherein the improving comprises reducing or preventing a roughness of the target tissue or maintaining the smoothness of the target tissue.

40. The method of embodiment 38 or embodiment 39, wherein the improving comprises reducing or preventing wrinkles and fine lines in the target tissue.

41. The method of any one of embodiments 38 to 40, wherein the target tissue is undereye skin and the improving comprises reducing the appearance of dark circles in the target tissue.

42. The method of any one of embodiments 38 to 41 , wherein the improving comprises reducing or preventing a redness of the target tissue.

43. The method of any one of embodiments 38 to 42, wherein the improving comprises increasing or maintaining a glossiness and/or brightness of the target tissue.

44. A method of improving a well-being of a subject exposed to a light emitted from a non-uniform light-emitting source, comprising topically applying a light-modulating cosmetic composition of any one of embodiments 1 to 21 or a consumer product of any one of embodiments 22 to 24 to a target tissue.

45. The method of embodiment 44, wherein the improving comprises decreasing stress.

46. The method of embodiment 44 or embodiment 45, wherein the improving comprises increasing chakra energy. 47. The method of any one of embodiments 25 to 46, wherein the non-uniform light-emitting source is one or more of a computer, a tablet, a mobile phone, a television, a fluorescent light, a light emitting diode (LED), or any other digital device or artificial light source comprising a light source that emits non-uniform light, optionally wherein at least one non-uniform emission wavelength is in the blue light spectrum.

48. The method of any one of embodiments 25 to 47, further comprising exposing the target tissue to a natural light source.

49. The method of any one of embodiments 25 to 48, wherein the target tissue is skin, optionally a facial skin, hair, and/or nails.

50. A method of making a consumer product, comprising: (a) adding to a cosmetic base a lightmodulating cosmetic composition of any one of embodiments 1 to 21 to form a mixture; (b) stirring the mixture to achieve homogeneity; (c) optionally emulsifying the mixture; (d) optionally cooling the mixture; and (e) optionally adjusting the pH of the mixture.

51. The method of embodiment 50, wherein the cosmetic base comprises one or more of water, emollients, humectants, gelling agents, emulsifiers, oils, waxes, preservatives, fragrance, actives ingredients, pigments, sunscreens, colorants, chelatants, or antioxidants.

52. A kit comprising a light-modulating cosmetic composition according to any one of embodiments 1 to 21 and instructions for use.

VI. EXAMPLES

[0098] The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

EXAMPLE 1: Assessment of photoluminescent compound optical features

[0099] A mixture of three different photoluminescent compounds, fluorescent xanthenic dyes Eosin Y, Fluoresceine, and Phloxine, was solubilized at 0.4% into glycerin. The photoluminescent mixture was solubilized at 1 % into a transparent gel (Test Mix; see, Table El) to assess the fluorescence and light- transforming properties of the photoluminescent compounds in vitro.

[00100] Table El: Transparent gel test compositions.

A. Absorption and emission spectrum

[00101] The absorption spectrum was recorded by means of a UV-Vis spectrophotometer Cary 5 E. The emission spectrum (with excitation at 455 nm) was recorded with a Spectrofluorometer (Fluorolog FL-3).

[00102] As shown in FIG. 1, the Test Mix exhibited fluorescence properties, absorbing light between 400 and 550 nm and reemitting at higher wavelengths. When exposed to a wavelength of 455 nm, the Test Mix converted the monochromatic light into a range of 500-600 nm, yielding an overall orange light emission.

B. Optical features under digital screen illumination

[00103] To assess the photoluminescent mixture efficacy in the gel, illuminance (lux) measurements were completed according to the set-up shown in FIG. 2. Test Mix or Placebo was spread at 2 mg/cm² on a transparent PVC foil placed at 30 cm from a computer screen or smartphone screen. An illuminance meter (CL70 F Konica Minolta) was located immediately behind the PVC foil and measured the illuminance of the digital screen light as transmitted by the gel. This design mimics the average distance between the screen and the skin of the face when a person works in front of a computer.

[00104] Screen emissions through the Test Mix and Placebo were recorded from 380 nm to 780 nm in the dark, in the vicinity of a window (natural light conditions), and under artificial light (LED panels). The illuminance meter records the illuminance (expressed in lux), representing the luminous flux (in lumen) received per surface unit (in m²). This measurement represents the amount of incident light illuminating a surface. [00105] Depending on the wavelength, a conversion between lux and W/m² can be obtained based on the spectral distribution: Illuminace = Radiant flux x S, where S is a factor of correction obtained with the spectral distribution (ISO 18526-2). The irradiance (expressed in W. m². nm ¹ ). represents the radiant flux of light received by a surface. It is the power per unit area received on a defined surface at a given moment. For example, the S factor at 455 nm is equal to 0.2667. Therefore, a radiant flux of 1 W/m² at this wavelength corresponds to 0.2667 lux.

[00106] The computer screen emitted an irregular spectrum displaying 3 distinct peaks. As shown in FIG. 3, the main peak is situated at 450-455 nm, in mid-blue light range and corresponds to the absorption range of photoluminescent compounds. Two other peaks, with lower intensity, are positioned at 540 and 590 nm.

[00107] When illuminated by the computer screen at 30 cm, the Test Mix was able to decrease the irradiance at 450 nm up to -16% regardless of the light environment (FIG. 4A). At the same time, the Test Mix provided an increase of irradiance at 600 nm particularly under natural light and dark conditions (up to +7 %) (FIG. 4A). The impact on the intermediate wavelength 540 nm was negligible. Similar' results were observed when illuminated with a smartphone screen at 30 cm (FIG. 4B).

[00108] As shown in Tables E2 and E3, the distance of the digital screen also impacted the modulation of irradiance. The experiments to assess the impact of screen distance were conducted in the presence of a combination of natural and artificial light to mimic a “classical office” environment.

Table E2: Irradiance (W/m²) at 450 nm, 540 nm, and 600 nm when illuminated by a computer screen at different distances (cm) under “classical office” conditions.

Table E3: Irradiance (W/m²) at 450 nm, 540 nm, and 600 nm when illuminated by a smartphone screen at different distances (cm) under “classical office” conditions.

[00109] The duration of the photoluminescent compound mixture’s effect on irradiance was assessed by illuminating the Test Mix with a computer screen at 30 cm and measuring the irradiance at 450 nm, 540 nm, and 600 nm hourly for 8 hours. As shown in FIGS. 4C-4E, the measured irradiance varied about or below 10% for each wavelength, demonstrating the stability of the photoluminescent compounds effect.

[00110] These data are supportive of the ability of the photoluminescent compound mixtures to modulate the irradiance of light emitted from non-uniform light-emitting sources. These data demonstrate the ability of the photoluminescent compound mixtures to absorb harmful blue light from such sources and increase the irradiance at higher (longer) wavelengths without impacting the intermediate wavelengths. This modulation results in a more balanced irradiance across wavelengths. These data further support the stability of the photoluminescent compounds effect.

EXAMPLE 2: Assessment of photoluminescent compound effects on skin explants

[00111] Exposure of human skin to blue light is known to induce serious skin damage leading to premature aging, wrinkles, etc. The effects of the photoluminescent compounds on DNA oxidation, cytochrome c oxidase activity, and opsin expression in human skin exposed to blue light were assessed using skin cxplants.

[00112] A total of 30 human skin biopsies were obtained from a plastic surgery patient (Caucasian woman, 32 years old). Each explant was kept in survival medium for 8 days and irradiated every day for 3 hours with blue light from a Solarbox® device (59 W/m² at 455 nm) corresponding to a radiation dose of 63.75 J/cm². Test Mix or Placebo (see. Table El of Example 1) was applied topically before irradiation, at day 0 (DO), DI, D4, and D6. An untreated, unexposed group and an untreated, exposed group served as controls. At D8, explants were fixed and directly frozen for 8-OHdG and opsins immunostaining.

A. DNA Oxidation

[00113] 8-hydroxydesoxyguanosine (8-OHdG) is one of the predominant forms of free radical- induced oxidative lesions in humans. This stable oxidative modified DNA product reflects the degree of oxidative damage to DNA. DNA oxidation in explants was detected by labelling 8- OHdG using a monoclonal anti-8-OHdG antibody coupled with biotin and revealed by substrate of peroxidase.

[00114] Compare to untreated unexposed conditions, the percentage of 8-OHdG staining increased by +113% and +118% for untreated and Placebo conditions exposed under blue, respectively (FIG. 5). Inversely, the Test Mix reduced staining for 8-OHdG, by 89% compared to placebo.

[00115] These data are supportive of the ability of the photoluminescent compounds to reduce blue light-evoked DNA oxidation.

B. Cytochrome c oxidase (CCO) activity

[00116] In cells, the main function of mitochondria is to generate most of the chemical energy needed to power cell’s biochemical reactions. Most part of this machinery is in the inner mitochondrial membrane and includes the four electron transfer chain complexes (complex I, II, ITT and TV), ATP synthase (complex V) ubiquinone and cytochrome c as electron carrier. The complex IV or cytochrome c oxidase (CCO) is the terminal enzyme of the electron transport chain which is involved in reduction of cytochrome c to oxygen to make H2O and in activation of complex V activation to synthesize ATP. Moreover, the respiratory chain of mitochondrial contributes to ROS (reactive oxygen species) production within cells. All mitochondrial activities arc sensitive to light exposure since mitochondria contain photosensitive chromophore, such as CCO, that can be activated or inhibited by light in the visible range. Blue light exposure is known to increase the ROS production by a deregulation of CCO activity leading to skin damage.

[00117] To evaluate cytochrome c oxidase (CCO) activity, the frozen skin explants were lysed with an ultrasonic system and after centrifugation the supernatants were collected to evaluate by an enzymatic method based on the measures of the oxidation rate of reduced cytochrome C through the activity of CCO.

[00118] As shown in FIG. 6, blue light exposure increased CCO activity by 96% and 114.5% in untreated and placebo condition compared to untreated condition without blue light. However, the Test Mix restored the blue light effect on CCO activity by a decrease of 81% compared to placebo condition (FIG. 6).

[00119] These data are supportive of the ability of the photoluminescent compounds to reduce blue light-evoked CCO activity.

C. Opsin Expression

[00120] Opsin 1SW and opsin 2 receptors are expressed on the surface of the skin, and their expressions are sensitive to light excitation. These cutaneous photoreceptors are sensitive to the light absorbed by the skin and each opsin has a distinct absorption spectrum and signal transduction, and their expressions depend on the skin’s exposure to light. Epidermal expression of opsin 1SW and opsin 2 has been found to increase after exposure to wavelengths between 355 and 470 nm, and at 500nm.

[00121] To detect opsin 1SW and opsin 2 expressions in the skin explants treated as described above, the opsins were respectively labeled with polyclonal anti-Opsin 1SW and monoclonal antiopsin 2, both revealed by A488 secondary antibody, then the quantification was performed by image analysis using Imagel® software (FIGS. 7A-7C).

[00122] As shown in FIGS. 7A-7C, compared to the untreated, unexposed control, Opsin 1SW levels increased and Opsin 2 levels decreased in both the untreated and the placebo exposed groups. However, in the presence of the Text Mix, Opsin 1SW expression decreased by 22% and Opsin 2 increased by 12% vs. placebo (FIG. 7C). [00123] These results are supportive of the ability of photoluminescent compounds to modify the spectrum of incoming light, protecting the skin from the effects of blue light and allowing the activation of photosensitive molecules through to the re-emission of light at higher wavelengths.

EXAMPLE 3: Assessment of photoluminescent compound effects on cellular communication

[00124] On average our bodies are made of 60% water that comprises our intracellular and extracellular fluids. The water is an interface, an environment, and a support of interaction between cell and biological field. Water is therefore a living, dynamic, highly mobile, and able to transmit vital information to living cells. Withing living organism, the water is structured due to the presence of electromagnetic field coming for electrical activity product by several different types of cells, including neurons, endocrine and muscle cells but also entities exhibited within the skin such as sweat gland. Structured water refers to increases in the numbers of aggregated hydrogen and oxygen atoms that form a cluster comprising 2 to hundreds of water molecules and this structured water is some energy modulators due to this ability to transfer proton and electron. Indeed, structured water is described as a vector involved in the transmission of biological information.

[00125] To assess the ability of the photoluminescent compounds to increase the transmission of biological information, 0.00015% of the photoluminescent mixture (see, Example 1) was mixed with ultrapure water electro magnetized during 5 min at less than 10’⁴ nanotesla by using the method of Poyinting vector. Following exposure to blue light at 482 nm, the emission spectrum of photoluminescent mixture was evaluated at 506 nm using a spectrophotometer. In parallel, a drop of the water mixture was evaporated at room temperature in a desiccator for 2 days, before exposure to blue light at 482 nm and the water structuration was observed with epifluorescence microscopy (obj 40X).

[00126] Following blue light exposure, the transformation of blue light at 512 nm was increased by 31% (FIG. 8 A). The results suggest that the electromagnetic field improved the properties of the photoluminescent compounds. Using epifluorescence microscopy, the photoluminescent compounds followed the path of the structured water (FIGS. 8B-8C).

[00127] These results suggest that the photoluminescent compounds have the ability to improve cellular communication by combining its own energy with that produced by structured water. EXAMPLE 4: Visualization of light conversion by photoluminescent compounds

[00128] The ability of the photoluminescent compounds to absorb blue light emit at higher wavelengths was evaluated in a clinical study.

[00129] Healthy volunteers applied the Clinical Test Mix and Clinical Placebo (see, Table E4) following a randomized hemiface design. By means of a full-face hyperspectral analysis using Spectracam®, emissions at 560 nm were recorded after blue light excitation at 405 nm, immediately and 10 min after application. A negative control was performed without blue light exposure.

Table E4: Gel-cream test compositions for clinical studies.

[00130] Without blue light exposure, no emission at 560 nm was observed whereas under excitation with blue light (405 nm), the hemiface that received the Test Mix emitted light at 560 nm (FIG. 9A). By grayscale evaluation, it was observed that compared to placebo, the emission at 560 nm under exposure to blue light increased by 73% and 96.5% on the forehead and cheek immediately after application of Test Mix. This effect was maintained over time. As shown in FIG. 9B, an increase of 77% and 94% on the forehead and cheek, respectively, compared to placebo side was observed 10 min after application.

[00131] These data are supportive of the ability of the photoluminescent compounds to absorb blue light and reemit at higher wavelengths when applied topically. These data further suggest that the photoluminescent compounds can maintain this ability over time. EXAMPLE 5: Assessment of photoluminescent compounds on skin appearance

[00132] The effects of the photoluminescent compounds on skin appearance were investigated in a clinical study involving healthy volunteers spending time in front of light sources emitting blue light.

[00133] A multi-ethnic panel of 37 healthy female and male volunteers, (30 to 50 years old), spending at least 6 hours a day working on computers without blue light filters and who do not wear glasses was recruited. The volunteers, divided in 2 groups, applied the Clinical Test Mix or Clinical Placebo (see, Example 4, Table E4) twice a day, morning and evening. At D28, the color of the volunteers’ undereye dark circles was evaluated by measuring the ITA° parameter by using Visia-CR, the skin’s anti-oxidative potential was analyzed using a Comeofix®, the skin’s redness was evaluated by Visia-CR RBX®, the glossiness of skin was measured by spectrophotometer CM-700D, and the wrinkles volumes and roughness were assessed by prime 3D.

[00134] As shown in FIGS. 10A-10B, compared to the Clinical Placebo, the Clinical Test Mix lightened the color of dark circles by 12.5% and the anti-oxidative potential increased by 14% at 28 days. Skin redness (FIG. 10D) and the glossiness (FIG. 10C) evaluations showed, respectively, a decrease by 18% and an increase by 41.5% compared to Clinical Placebo. These results support the ability of the photoluminescent compounds to increase skin health appearance and protect the skin. Furthermore, as these skin parameters are associated with skin age appearance, the application of Clinical Test Mix decreased skin wrinkles volume by 13.5% and skin roughness by 8% (FIGS. 10E-10F).

[00135] These clinical results demonstrate the beneficial effects of the photoluminescent compounds on skin appearance, skin protection, and reduction of skin aging. These results suggest that the transformation of blue light to higher wavelengths accomplished by the photoluminescent compounds can protect and restore skin integrity.

EXAMPLE 6: Assessment of photoluminescent compounds on well-being

[00136] The ability of the photoluminescent compounds to impact subject well-being was evaluated.

[00137] Stress and chakra energy were assessed in a multi-ethnic panel of 15 healthy female and male volunteers, (30 to 50 years old), spending at least 6 hours a day working on computers without blue light filters and who do not wear glasses. These volunteers, divided in 2 groups, applied the Clinical Test Mix or Clinical Placebo (see, Example 4, Tabic E4) twice a day, morning and evening. At D28, stress and the chakra energies were assessed for each volunteer using Biowell®.

[00138] As shown in FIGS. 11A-11C, stress decreased by 42.5% and all chakra energies increased among volunteers who applied the Clinical Test Mix compared to the Clinical Placebo. Overall, chakra energy increased by 25.5% compared to Clinical Placebo measures.

[00139] These results support that the photoluminescent compounds can transform blue light emitted by screen devices or other artificial light sources into a more balanced light, with emissions in higher wavelengths and that this has a positive effect on well-being.

[00140] The present invention is not intended to be limited in scope to the particular disclosed embodiments, which are provided, for example, to illustrate various aspects of the invention. Various modifications to the compositions and methods described will become apparent from the description and teachings herein. Such valuations may be practiced without departing from the true scope and spirit of the disclosure and are intended to fall within the scope of the present disclosure. Although the invention may be described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in chemistry, cosmetics, optics, physics, and related fields are intended to be within the scope of the following claims.

Claims

WHAT IS CLAIMED IS:

1. A light-modulating cosmetic composition comprising one or more photoluminescent compounds, wherein the composition modulates an irradiance of a non-uniform light-emitting source on a target tissue, optionally wherein the target tissue is skin, hair, and/or nails.

2. The light-modulating cosmetic composition of claim 1, wherein the composition modulates the irradiance of the non-uniform light-emitting source to produce a white light.

3. The light-modulating cosmetic composition of claim 1 or claim 2, wherein the composition comprises at least 2 different photoluminescent compounds, each compound having at least one absorption peak wavelength in a range of about 380 to about 500 nm, at least one compound having an emission peak wavelength in a range of about 500 to about 575 nm, and at least one other compound having an emission peak wavelength in a range of about 575 to about 780 nm.

4. The light-modulating cosmetic composition of any one of claims 1 to 3, wherein the composition comprises at least 3 different photoluminescent compounds.

5. The light-modulating cosmetic composition of any one of claims 1 to 4, wherein the composition comprises at least one photoluminescent compound having an emission peak wavelength in a range of about 400 to about 500 nm.

6. The light-modulating cosmetic composition of any one of claims 1 to 5, wherein:

- at least one compound having an emission peak wavelength in a range of about 500 to about 575 nm is selected from Octahydrocoumarin, Fluorescein, Eosin Y, Tartazine, 2h-l- benzopyran-2-one, Daphnetin, Coumarin, 7-Diethylamino-4-methylcoumarin, Quinoline, Scoparone, Curcurmine, and Naphthalimide; and/or

- at least one other compound having an emission peak wavelength in a range of about 575 to about 780 nm is selected from Phloxine, Rhodamine B, Rhodamine 6G, Benzopyran, and Cyanine.

7. The light-modulating cosmetic composition of any one of claims 1 to 6, wherein the composition comprises at least one compound having an emission peak wavelength in a range of about 400 to about 500 nm selected from coumarin, aminocoumarin, and a disulphonic acid stilbene derivative.

8. The light-modulating cosmetic composition of any one of claims 1 to 7, wherein the total concentration of photoluminescent compounds in the composition is in a range of about 0.001% to about 20% weight of the composition.

9. The light-modulating cosmetic composition of any one of claims 1 to 8, wherein the composition comprises one or more of glycerin, water, a glycol derivative, a hydrogel, or other solvent or powder carrier acceptable for topical application.

10. The light-modulating cosmetic composition of any one of claims 1 to 9, wherein the non-uniform light-emitting source is one or more of a computer, a tablet, a mobile phone, a television, a fluorescent light, a light emitting diode (LED), or any other digital device or artificial light source comprising a light source that emits non-uniform light, optionally wherein at least one non-uniform emission wavelength is in the blue light spectrum.

11. A consumer product comprising a light-modulating cosmetic composition of any one of claims 1 to 10, wherein the consumer product is a cream, a lotion, a gel, a foam, a paste, a salve, a balm, a varnish, or an ointment.

12. The consumer product of claim 11, wherein the consumer product is a skin care product, a body care product, a hair care product, a make-up product, a nail care product, or a baby care product.

13. The consumer product of claim 11 or claim 12, wherein the total concentration of photoluminescent compounds in the consumer product is in a range of about 0.001% to about 0.1% weight of the consumer product.

14. A method of modulating an irradiance from a non-uniform light-emitting source on a target tissue, comprising topically applying a light-modulating cosmetic composition of any one of claims 1 to 10 or a consumer product of any one of claims 11 to 13 to a target tissue, optionally wherein the target tissue is skin, hair, and/or nails.

15. A method of making a consumer product, comprising:

(a) adding to a cosmetic base a light-modulating cosmetic composition of any one of claims 1 to 10 to form a mixture;

(b) stirring the mixture to achieve homogeneity;

(c) optionally emulsifying the mixture;

(d) optionally cooling the mixture; and

(e) optionally adjusting the pH of the mixture.